Last C$0.06 CAD
Change Today 0.00 / 0.00%
Volume 0.0
MIR On Other Exchanges
Symbol
Exchange
Venture
Frankfurt
As of 3:59 PM 11/26/14 All times are local (Market data is delayed by at least 15 minutes).

medmira inc (MIR) Snapshot

Open
C$0.06
Previous Close
C$0.06
Day High
C$0.06
Day Low
C$0.06
52 Week High
01/29/14 - C$0.14
52 Week Low
11/28/13 - C$0.05
Market Cap
29.5M
Average Volume 10 Days
85.9K
EPS TTM
C$-0.0090
Shares Outstanding
536.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for MEDMIRA INC (MIR)

Related News

No related news articles were found.

medmira inc (MIR) Related Businessweek News

No Related Businessweek News Found

medmira inc (MIR) Details

MedMira Inc., a biotechnology company, is engaged in the research, development, manufacture, and sale of rapid diagnostics and technology platforms. Its research is focused on specific areas of the diagnostics market, including rapid, point-of-care, and in vitro sectors. Its products include Reveal HIV, which detects antibodies to HIV-1 and HIV-2 in whole blood, serum, or plasma; Reveal HP/Rapid H. Pylori antibody tests that detect helicobacter pylori (HP) antibodies in serum, plasma, or whole blood produced in response to HP infection; Reveal TP, a rapid syphilis antibody test, which detects treponema pallidum (TP) antibodies; Multiplo, a line of multiplex tests that combines testing solutions for HIV-1/2, Hepatitis B and C, and Syphilis in whole blood, serum, or plasma; and Miriad developer toolkit that facilitates the development and commercialization of rapid diagnostics. MedMira Inc. sells its rapid tests through a network of medical distributors and strategic business development partners with customers in various sectors of the healthcare industry, including laboratories, hospitals, point-of-care facilities, governments, and public health agencies. The company sells and distributes its products in North America, Latin America and the Caribbean, Europe, the Asia Pacific, and the Middle East. MedMira Inc. has collaboration with National Research Council of Canada. The company was founded in 1993 and is headquartered in Halifax, Canada. MedMira Inc. operates as a subsidiary of Onsite Lab Holding AG.

Founded in 1993

medmira inc (MIR) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: C$188.0K
Compensation as of Fiscal Year 2013.

medmira inc (MIR) Key Developments

MedMira Inc. Names Robyn Cook as Chief Corporate Officer

MedMira Inc. announced that Robyn Cook has been appointed as the company's Chief Corporate Officer, effective immediately. Ms. Cook most recently served as MedMira's Senior Director of Corporate Governance. She will continue in her role as the company's Corporate Secretary. Ms. Cook brings a wealth of experience to the position of Chief Corporate Officer, built on over 14 years working in a variety of progressively senior roles at MedMira, spanning corporate governance, compliance, operations, business process and policy development, and human resources. As Chief Corporate Officer, Ms. Cook will focus on organizational alignment and prioritization of corporate strategy, implementation of industry best practices, and maximizing excellence across all MedMira business units. Prior to joining MedMira, Ms. Cook worked in the energy and education sectors.

Beacon Biomedical LLC Engages Medmira Inc. to Develop a Rapid Colon Cancer Test on Its Patented Rapid Vertical Flow Technology Platform

MedMira Inc. has been engaged by Beacon Biomedical LLC to develop a rapid colon cancer test on its patented Rapid Vertical Flow (RVF) Technology(TM) platform. The test will detect Cripto-1 (CR-1), a protein biomarker associated with early tumor formation and progression. Beacon Biomedical has secured the exclusive global development and commercialization rights for rapid oncology-based tests using this biomarker from the National Cancer Institute (NCI) at the National Institutes of Health (NIH) in the United States.

MedMira Inc. Expands its Multiplo Product Line with the Addition of Three New Multiplex Tests

MedMira Inc. is expanding its Multiplo product line with the addition of three new multiplex tests that deliver instant, simultaneous, single-cartridge results for syphilis (TP), HIV, and hepatitis C. The new tests being added to the product range include Multiplo TP/nTP, which detects both active and historic syphilis infections, Multiplo TP/HIV/nTP, and Multiplo TP/HIV/HCV, which simultaneously detects syphilis, HIV and hepatitis C. The full Multiplo line is now available in international markets with analysis of highly regulated markets, possibly including North America and Europe, underway. MedMira will showcase its full Multiplo line for the first time at the 2014 American Association for Clinical Chemistry (AACC) Annual Meeting &Clinical Lab Expo. The new tests all deliver instant results for syphilis infection, a disease with an increasing global prevalence rate. Multiplo TP/nTP and Multiplo TP/HIV/nTP take testing a step further, providing comprehensive screening and confirmatory results for both present and past syphilis infections. Detecting the presence of both current and previous infections provides critical information to help healthcare providers in determining the right course of treatment for their patients.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MIR:CN C$0.06 CAD 0.00

MIR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for MIR.
View Industry Companies
 

Industry Analysis

MIR

Industry Average

Valuation MIR Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 12.8x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 11.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MEDMIRA INC, please visit www.medmira.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.